Key Events This Week
Apr 20: Stock opens at Rs.2,229.65, down 0.81%
Apr 21: Modest recovery with Rs.2,232.95 close (+0.15%)
Apr 22: Continued gains to Rs.2,241.55 (+0.39%)
Apr 23: New 52-week and all-time highs at Rs.2,322.75 and Rs.2,312.15; sharp open interest surge
Apr 24: Further 52-week high at Rs.2,371.6; mixed price action with open interest rising 19.5%
Monday, 20 April 2026: Weak Start Amid Broader Market Stability
Glenmark Pharmaceuticals began the week on a subdued note, closing at Rs.2,229.65, down 0.81% from the previous Friday’s close of Rs.2,247.90. This decline contrasted with the near-flat Sensex, which slipped marginally by 0.02% to 35,814.68. The stock’s volume was moderate at 14,742 shares, reflecting cautious investor sentiment ahead of anticipated corporate developments.
Tuesday, 21 April 2026: Modest Recovery with Market Rally
The stock rebounded slightly to close at Rs.2,232.95, gaining 0.15%, while the Sensex rallied 0.77% to 36,091.30. Volume increased to 17,303 shares, indicating renewed buying interest. Glenmark’s relative underperformance versus the Sensex suggested investors were awaiting further news to confirm the stock’s direction.
Wednesday, 22 April 2026: Steady Gains and Rising Open Interest
Glenmark advanced 0.39% to Rs.2,241.55 on lighter volume of 7,445 shares, while the Sensex declined 0.23%. Notably, derivatives market activity surged with open interest rising sharply by 31.3% to 47,578 contracts, signalling increased bullish positioning among traders. This heightened activity foreshadowed the strong price moves to come.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Thursday, 23 April 2026: Breakout to New Highs on Robust Financials
Glenmark Pharmaceuticals surged 4.27% to close at Rs.2,337.20, hitting a new 52-week high of Rs.2,322.75 and an all-time high close of Rs.2,312.15. This rally was supported by strong financial results showing net sales growth of 45.83% and profit after tax rising to Rs.2,026.77 crores for the latest six-month period. The stock outperformed the Sensex, which fell 0.78%, and the Pharmaceuticals & Biotechnology sector by 1.64%.
Derivatives activity intensified with open interest climbing 31.3%, and futures and options turnover reaching ₹2,20,932 lakhs, reflecting active positioning for further gains. Despite the strong price action, delivery volumes declined by 29.22%, suggesting momentum was driven by short-term traders and derivatives players rather than long-term holders.
Friday, 24 April 2026: New Highs Amid Mixed Price Action and Elevated Volatility
The stock reached a fresh 52-week high of Rs.2,371.6 and an all-time high close of Rs.2,370.5, despite a day decline of 1.68% to Rs.2,298.05. This pullback followed four consecutive days of gains, indicating a short-term profit-taking phase amid sustained bullish momentum. Glenmark outperformed the Sensex, which dropped 1.06%, and its sector by 1.4%.
Open interest surged again by 19.5% to 46,931 contracts, with futures and options notional values of ₹1,30,197 lakhs and ₹28,575.6 crores respectively, underscoring the stock’s prominence in the derivatives market. Delivery volumes spiked by 174.63%, signalling renewed investor participation. Technical indicators remained bullish, with the stock trading above all key moving averages and supported by positive MACD and Bollinger Bands signals.
Curious about Glenmark Pharmaceuticals Ltd. from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-20 | Rs.2,229.65 | -0.81% | 35,814.68 | -0.02% |
| 2026-04-21 | Rs.2,232.95 | +0.15% | 36,091.30 | +0.77% |
| 2026-04-22 | Rs.2,241.55 | +0.39% | 36,009.59 | -0.23% |
| 2026-04-23 | Rs.2,337.20 | +4.27% | 35,729.71 | -0.78% |
| 2026-04-24 | Rs.2,298.05 | -1.68% | 35,349.66 | -1.06% |
Key Takeaways
Strong Financial Performance: Glenmark’s robust net sales growth of 45.83% and profit after tax of Rs.2,026.77 crores for the latest six months underpin the stock’s upward momentum.
Technical Strength: The stock consistently traded above all major moving averages, supported by bullish MACD and Bollinger Bands indicators, signalling sustained positive momentum.
Derivatives Market Activity: Sharp surges in open interest (31.3% on 22 April and 19.5% on 24 April) alongside high volumes indicate active positioning and strong market interest, though mixed delivery volumes suggest a blend of short-term trading and longer-term conviction.
Market Outperformance: Glenmark outperformed the Sensex by 3.54% over the week, highlighting its resilience amid broader market weakness.
Profit-Taking and Volatility: The slight pullback on 24 April after multiple new highs reflects healthy profit-booking and elevated intraday volatility, typical in strong trending stocks.
Institutional Confidence: With 39.67% institutional ownership and a Mojo Grade of Strong Buy, Glenmark enjoys solid backing from well-informed investors.
Conclusion
Glenmark Pharmaceuticals Ltd. demonstrated a strong and resilient performance during the week ending 24 April 2026, marked by multiple new 52-week and all-time highs, robust financial results, and heightened market activity in both cash and derivatives segments. The stock’s 2.23% weekly gain significantly outpaced the Sensex’s 1.31% decline, reflecting its leadership within the Pharmaceuticals & Biotechnology sector.
While short-term profit-taking and mixed delivery volumes suggest some caution, the overall technical and fundamental backdrop remains positive. The surge in open interest and trading volumes indicates active market participation and confidence in Glenmark’s growth prospects. Investors should monitor ongoing derivatives activity and price action for confirmation of sustained momentum.
Glenmark’s strong financial metrics, attractive valuation, and institutional support position it well within the mid-cap universe, making it a notable stock to watch amid current market dynamics.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
